Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck - Contacts and Locations

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

This study has been completed.

Study NCT00077428. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077428

Locations


United States, Florida
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
	Tampa, Florida, United States, 33612-9497

United States, New Hampshire
	Norris Cotton Cancer Center at Dartmouth - Hitchcock Medical Center
	Lebanon, New Hampshire, United States, 03756-0002

United States, Pennsylvania
	Hillman Cancer Center at University of Pittsburgh Cancer Institute
	Pittsburgh, Pennsylvania, United States, 15232
	Lewistown Hospital
	Lewistown, Pennsylvania, United States, 17044
	Mount Nittany Medical Center
	State College, Pennsylvania, United States, 16803
	Penn State Cancer Institute at Milton S. Hershey Medical Center
	Hershey, Pennsylvania, United States, 17033-0850

United States, Wisconsin
	Froedtert Hospital and Medical College of Wisconsin
	Milwaukee, Wisconsin, United States, 53226
	Medical College of Wisconsin Cancer Center
	Milwaukee, Wisconsin, United States, 53226

Sponsors and Collaborators

Eastern Cooperative Oncology Group

National Cancer Institute (NCI)

Southwest Oncology Group

Investigators


Study Chair:	Athanassios Argiris, MD	UPMC Cancer Centers

Investigator:	Barbara A. Burtness, MD	Yale University

Investigator:	Madeleine A. Kane, MD, PhD	University of Colorado at Denver and Health Sciences Center